NCT06136624 2026-03-11
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
7 trialsNCT03850795 2024-08-19
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Hinova Pharmaceuticals USA, Inc.
Phase 3 Terminated
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT02814968 2022-04-14
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT02815033 2022-04-14
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT02407054 2021-05-11
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02379390 2019-06-21
PRIMCAB
Sanofi
Phase 2 Terminated